IBB News 270.92 09/05/2014 05:05:38 Nasdaq Biotechnology Ishares

New Post Public Reply Private Reply Replies (0) Message Board

Sep 5, 2014 at 6:05 AM

Nasdaq Biotechnology Ishares (IBB) 270.92 $IBB

Watch for iShares Nasdaq Biotechnology Index to Potentially Rebound After Falling 1.65% Yesterday
Comtex SmarTrend(R) - Thu Sep 04, 3:50PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $270.23 to a high of $276.22. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $273.85 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

iShares Nasdaq Biotechnology Index Set to Possibly Rebound After Yesterday's Selloff of 1.65%
Comtex SmarTrend(R) - Thu Sep 04, 3:50PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $270.23 to a high of $276.22. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $273.85 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?

After Recent Surge, Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?

Biotech Stock Boom Times Are Back
at The Street - Tue Aug 26, 6:00AM CDT
The iShares Nasdaq Biotechnology ETF closed at 272.63 Monday, less than one point below the year (and all-time) closing high reached on Feb. 25.

'Fast Money' Recap: Next Stop, S&P 2,100?
at The Street - Tue Aug 26, 4:00AM CDT
The trading panel looked at banks and the top buy and sell candidates for right now.

Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Pullback after Yesterday's 2.33% Rise
Comtex SmarTrend(R) - Mon Aug 25, 4:07PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $268.75 to a high of $272.88. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $268.60 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

After Yesterday's Rally of 2.33% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 25, 4:06PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $268.75 to a high of $272.88. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $268.60 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Economic Recovery Doesn't Satisfy Fed as Stocks Soar Higher
at The Street - Thu Aug 21, 10:14AM CDT
Low inflation and slack in the labor market has kept policymakers dovish, leading to strength in U.S. equities and in high-beta sectors.

Nasdaq Composite: What Are You Buying That's Driving New Highs? - Real Time Insight
Zacks Equity Research - ZACKS - Mon Aug 18, 1:04PM CDT
It's not just the big caps attracting all the money

Eased Geopolitical Tensions Have Little Effect on Interest Rates
at The Street - Fri Aug 15, 11:16AM CDT
It seems that no matter what, investors just want a reason to continue buying bonds and pressuring rates lower.

SmarTrend Watching for Potential Pullback in Shares of iShares Nasdaq Biotechnology Index After 2.17% Gain
Comtex SmarTrend(R) - Wed Aug 13, 3:58PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $252.61 to a high of $257.59. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $254.75 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

iShares Nasdaq Biotechnology Index Rises 2.17% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Aug 13, 3:58PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $252.61 to a high of $257.59. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $254.75 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

'Fast Money' Recap: Can You Trust This Rally?
at The Street - Tue Aug 12, 4:00AM CDT
The trading panel discussed whether the Federal Reserve is having more of an effect on the markets than geopolitical events.

'Fast Money' Recap: Is Michael Kors Still in Fashion?
at The Street - Tue Aug 05, 4:00AM CDT
The trading panel looked at Michael Kors' earnings, Microsoft, steel stocks and biotechs.

Biotech Earnings Put These ETFs in Focus - ETF News And Commentary
Zacks Equity Research - ZACKS - Thu Jul 31, 9:01AM CDT
Following solid results from Amgen, among others, these biotech ETFs could be ones to watch.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Navigating Simultaneous Home Buy and Sell Strategies

Juggling Two Housing Transactions You ever tried juggling chainsaws? That's what buying and selling your home at the same time can feel like. Selling First: Playing It Safe Some folks swear by selling their current home first, and there's good reason. It locks in your financial windfall, giving you a clear picture of your down payment and affordability. No more guessing...

Villas of Distinction Shines: Bags 11th Gold Travvy

Claiming Top Spot Repeatedly Another year, another accolade—Villas of Distinction has clutched its 11th Gold Travvy Award for "Best Villa Rental Company – Overall." This accolade ain't no small potatoes, as it's a testament to the company's unwavering excellence recognized by travel advisors worldwide. These folks, who have their fingers on the pulse of the industry,...

Stellus Capital Delivers Solid Q3 Amid Turbulent Times

Unpacking Stellus Capital's Latest Quarter Boy, Stellus Capital sure knows how to keep us on our toes. In a landscape where many are still reeling from the latest market tremors, they post some solid Q3 numbers for September 30, 2026. Not without its hiccups, but hey, who isn’t stumbling a bit right now? Financial Snapshot: Stability Amidst Uncertainty Stellus reported...

GCC's Path to 10 Gbps: U6GHz Revolution Unfolds

On the Journey to 10 Giga: The U6GHz Leap You know, sometimes the telco world kicks up a fuss about speed, and this time, it’s the upper 6 GHz (or U6GHz) band that’s got everyone abuzz. At the Telecom Review Leaders' Summit in Dubai, industry bigwigs gathered to discuss how this spectrum could catapult the GCC into the 10 Gbps connectivity stratosphere. Fancy-talk...

Cohen & Steers Sees Steady Rise in October AUM

Market Pushes Cohen & Steers Forward It's been a wild ride for financial managers lately, and Cohen & Steers, Inc. (NYSE: CNS) isn't exempt from the rollercoaster. As of October 31, 2026, they've reported assets under management (AUM) climbing to $99.6 billion—thanks to a hefty market appreciation of $4 billion. Not too shabby when you're dealing with the...

Texas Author's Memoir Journeys Through Trauma and Growth

Finding Clarity Amid Chaos When life throws the unexpected, some folks crumble, but others, like Joyce L. Skala, sift through the rubble for clarity. Her debut memoir, "There's No Such Thing as Bad," weaves through personal chaos—embracing trauma and loss like a late-night poker game where the house always wins. Born from the charred memories of her family's home...

Ionis Faces Legal Scrutiny Amid Slashed Sales Forecast

Ionis Pharmaceuticals Takes a Hit: What's Happening? November 9, 2026, wasn't just another dreary market day—especially if you've got a stake in Ionis Pharmaceuticals. Today, they whittled down their full-year sales forecast for TRYNGOLZA from a cozy $100 million to $110 million range to a startling $50 million. NASDAQ: IONS shares naturally took a nosedive, and as...

TCL Tablets Arrive on BestBuy.com: What It Means

Go Big or Go Home: TCL's Bold Move TCL just dropped a little bombshell that's gonna ripple through the electronics retail market—its tablets and smartphones are now bright and shiny on BestBuy.com. It's like standing at the craps table and before you know it, the stakes have just doubled. Why? Best Buy ain't some hole-in-the-wall spot. It's the premium electronics...

Quantinuum & RIKEN Propel Japan's Quantum Leap Forward

Quantum Computing: Japan's Bold New Frontier Quantum computing's buzz is getting louder, and the big players like Quantinuum and RIKEN ain't sitting on their hands. They've rolled up their sleeves to ramp up Japan's quantum-AI supercomputing game with the recent beef-up of Quantinuum's Reimei to its H2 system, putting Japan at the cutting edge of hybrid computing. The...

Routeware's AI Tech Transforming Waste Management

Transforming Waste Management through AI The waste and recycling game just got a facelift with Routeware's latest AI-powered tools. Right out of Austin, Texas, they're throwing down with Routeware Pulse, a fresh AI data and analytics platform that promises to revolutionize how operators handle their reporting and decision-making. It’s no fluff—they’re talking...